IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers

Neutralizing antibodies are key determinants of protection from future infection, yet well-validated high-throughput assays for measuring titers of SARS-CoV-2-neutralizing antibodies are not generally available. Here, we describe the development and validation of IMMUNO-COV v2.0, a scalable surrogat...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandergaast, Rianna, Carey, Timothy, Reiter, Samantha, Lathrum, Chase, Lech, Patrycja, Gnanadurai, Clement, Haselton, Michelle, Buehler, Jason, Narjari, Riya, Schnebeck, Luke, Roesler, Anne, Sevola, Kara, Suksanpaisan, Lukkana, Bexon, Alice, Naik, Shruthi, Brunton, Bethany, Weaver, Scott C., Rafael, Grace, Tran, Sheryl, Baum, Alina, Kyratsous, Christos A., Peng, Kah Whye, Russell, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265629/
https://www.ncbi.nlm.nih.gov/pubmed/34077262
http://dx.doi.org/10.1128/mSphere.00170-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265629/
https://www.ncbi.nlm.nih.gov/pubmed/34077262
http://dx.doi.org/10.1128/mSphere.00170-21

Ejemplares similares